Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- UBS sees dip buyers stepping in to support gold at this level
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.31 | 52 Week High | $42.49 | |||
| Open | $20.31 | 52 Week Low | $16.64 | |||
| Day High | $20.31 | P/E | N/A | |||
| Day Low | $20.31 | EPS | $-0.42 | |||
| Volume | 7,123 | |||||
